Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 12;14(9):e079539.
doi: 10.1136/bmjopen-2023-079539.

Developing films to support vaccine-hesitant, ethnically diverse parents' decision-making about the human papillomavirus (HPV) vaccine: a codesign study

Harriet Fisher  1 , Sarah Denford  2 , Tracey Chantler  3 , Suzanne Audrey  2 , Adam Finn  2   4 , Huda Hajinur  5 , Matthew Hickman  2 , Sandra Mounier-Jack  3 , Marion Roderick  6 , Leanne Tucker  7 , Julie Yates  8 , Asha Mohamed  5
Affiliations

Developing films to support vaccine-hesitant, ethnically diverse parents' decision-making about the human papillomavirus (HPV) vaccine: a codesign study

Harriet Fisher et al. BMJ Open. .

Abstract

Objective: To illustrate an evidence-, theory- and person-based approach to codesign the COMMUNICATE films that support parental decision-making about the human papillomavirus (HPV) vaccine for their teenagers.

Design: Codesign study.

Setting: Localities covered by two immunisation teams in London and the south-west of England.

Methods: The intervention planning phase involved combining evidence from a literature review with qualitative interview data to identify barriers and facilitators to HPV vaccine uptake, as well as design features that should be incorporated within the COMMUNICATE films. The intervention development phase involved identifying guiding principles for the COMMUNICATE films, mapping behaviour change techniques onto the behaviour change wheel and codesigning the COMMUNICATE films. Feedback from users informed modifications to maximise acceptability and feasibility and to support behaviour change.

Results: The primary and secondary evidence highlighted important content to include within the COMMUNICATE films: emphasise the benefits of the HPV vaccine, provide transparent information about the safety profile and side effects and emphasise the universality and commonality of HPV infection. A series of scripts were used to guide 4 film shoots to create the content in multiple community languages with 16 participants, including vaccine-hesitant, ethnically diverse parents and professionals. Overall, participants were positive about the films. Potential messengers and ways the films could be distributed, identified by parents, include local social media networks or text messages from general practices. The need for information about the HPV vaccine to be shared by schools ahead of consent being sought was also raised.

Conclusions: By using an integrated approach to intervention development, this study has begun to address the need for an intervention to support vaccine-hesitant, ethnically diverse parents' decision-making about the HPV vaccination programme. A future study to codesign, implement and evaluate a communication strategy for the COMMUNICATE films is planned.

Keywords: IMMUNOLOGY; PUBLIC HEALTH; Paediatric infectious disease & immunisation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AF is a member of the Joint Committee on Vaccination and Immunization and was, until December 2022, chair of the WHO European Technical Advisory Group of Experts on Immunization committee. The other authors have no relevant conflicts of interest to declare.

Figures

Figure 1
Figure 1. Intervention development overview adapted from the person-based approach.
See this image and copyright information in PMC

References

    1. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (Auckl) 2012;30 Suppl 5:F123–38. doi: 10.1016/j.vaccine.2012.04.108. - DOI - PMC - PubMed
    1. Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. 2015;136:e28–39. doi: 10.1542/peds.2014-3745. - DOI - PubMed
    1. UKHSA Human Papillomavirus (HPV) Vaccine Coverage Estimates in England 2021. 2022. https://www.gov.uk/government/collections/vaccine-uptake#hpv-vaccine-uptake Available.
    1. Fisher H, Evans K, Reynolds R, et al. Secondary analyses to test the impact on inequalities and uptake of the schools-based Human Papillomavirus (HPV) vaccination programme by stage of implementation of a new consent policy in the south-west of England. BMJ Open. 2021;11:e044980. doi: 10.1136/bmjopen-2020-044980. - DOI - PMC - PubMed
    1. Fisher H, Audrey S, Mytton JA, et al. Examining inequalities in the uptake of the school-based HPV vaccination programme in England: a retrospective cohort study. J Public Health (Oxf) 2014;36:36–45. doi: 10.1093/pubmed/fdt042. - DOI - PubMed

Publication types

Substances

LinkOut - more resources